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Abstract
Peritoneal Dialysis (PD) is considered the best option for a cost-effective mid-term dialysis
in patients with Chronic Renal Failure. However, functional failure of the peritoneal mem-
brane (PM) force many patients to stop PD treatment and start haemodialysis. Currently,
PM functionality is monitored by the peritoneal equilibration test, a tedious technique that
often show changes when the membrane damage is advanced. As in other pathologies, the
identification and characterization of extracellular vesicles (EVs) in the peritoneal dialysis
efflux (PDE) may represent a non-invasive alternative to identify biomarkers of membrane
failure. Using size-exclusion chromatography, we isolated EVs from PDE in a group of
patients. Vesicles were characterized by the presence of tetraspanin markers, nanoparticle
tracking analysis profile, cryo-electron microscopy and mass spectrometry. Here, we report
the isolation and characterization of PDE-EVs. Based on mass spectrometry, we have
found a set of well-conserved proteins among patients. Interestingly, the peptide profile also
revealed remarkable changes between newly enrolled and longer-treated PD patients.
These results are the first step to the identification of PDE-EVs based new markers of PM
damage, which could support clinicians in their decision-making in a non-invasive manner.
Introduction
Peritoneal Dialysis (PD) is a renal replacement technique based on the semipermeable charac-
teristics of the peritoneal membrane (PM). This membrane is composed by a monolayer of
mesothelial cells and an interstitial matrix with a high number of capillaries that, in the pres-
ence of hyperosmotic PD fluids, permits the removal of small, medium and, to a lesser extent,
large molecules, as well as water ultrafiltration. Prolonged exposure to PD fluids, the low pH of
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the solutions, as well as episodes of peritonitis or haemoperitoneum can cause detachment of
mesothelial cells, fibrosis and neovascularization of the PM, resulting in functional degrada-
tion. Although the mechanisms of peritoneal fibrosis are still under investigation, one of the
most accepted hypotheses is the epithelial to mesenchymal cell transition[1,2], involving fac-
tors such as vascular endothelial growth factor (VEGF) or tumour growth factor-β (TGF -β)
(reviewed in[3]). Thus, despite PD is considered the best alternative for cost-effective sustain-
ability of dialysis treatment[4,5], different changes ultimately lead to the failure of ultrafiltra-
tion of the PM, causing many patients to discontinue their treatment.
Monitoring the PM’s functional state is therefore of outstanding importance for patients’
management. Currently, PM is monitored based on the 4-hour lasting peritoneal equilibration
test (PET). PET data inform about the permeability and transfer characteristics of the PM, esti-
mating the water transport secondary to osmotic changes in the peritoneal cavity. These data
allow clinicians to estimate the peritoneal transport, set the dose and type of PD required for
each patient, and monitor the function of the PM. However, PET data render a delayed vision
of the status of the PM, as the functional failure only occurs in advanced fibrotic lesions. Thus,
monitoring early changes may help to identify and prevent functional worsening of the PM,
thus helping the clinician to apply the appropriate therapeutic tools to extend their functional-
ity. In this sense, efforts have been made on the proteomic analysis of peritoneal dialysis efflux
(PDE)[6–8].
In recent years, the study of extracellular vesicles (EVs) has gained enormous interest in the
diagnostic and therapeutic scenarios[9]. EVs are lipid-bilayered vesicles of 50 to 200 nm in
diameter produced by most cells, mainly containing proteins, RNAs and metabolites[10]. EVs’
main function is related to cellular communication[10,11], but as their specific composition
varies depending on the physiological and functional state of the producing cells, they have
been extensively reported as potential biomarkers in a variety of diseases, including those of
the renal system[12]. It is conceivable that the cells of the PM respond to the dialysis treatment
by secreting EVs, and that these EVs change their composition reflecting the physiological
state of the compartment of origin.
Here, our aim was to identify, isolate and characterize PDE-EVs of patients on PD. The
results show that PDE is a non-invasive feasible material to isolate EVs using conventional,
clinically applicable techniques. Analyses of PDE-EVs content permitted the identification of
specific peptide profiles that changed according to time on dialysis. Thus, the study of EVs
present in the PDE opens a new line of research to find non-invasive potential biomarkers for
the early detection of PM damage in PD patients.
Materials and methods
Patients
The Ethical Committee of “Germans Trias i Pujol” Hospital approved the study, and all sub-
jects gave their written consent according to the Declaration of Helsinki[13]. Inclusion criteria
were patients over 18 years old diagnosed of a renal disease requiring PD as chronic renal
replacement therapy. Patients starting PD due to heart failure, or those showing a peritonitis
episode in the previous two months were excluded. Also, patients showing changes in the peri-
toneal membrane transport type compared to their initial PET or patients showing ultrafiltra-
tion failure were also excluded. Nine patients (56% female) from our PD unit were considered
for the study. No patients presented any peritonitis episodes in the 2 months previous to the
study. Renal diseases included: 2 renal polycystic disease, 2 tubulointersticial nephritis, 4
glomerulonephritis and 1 unknown aetiology. Seven patients were on Continuous Ambulatory
Peritoneal Dialysis (CAPD) and 2 patients were on Automated Peritoneal Dialysis (APD).
Proteomic analysis of peritoneal dialysis efflux extracellular vesicles
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Seven patients were treated with icodextrin. Clinical and laboratory variables, Peritoneal Equil-
ibration Test (PET), type of peritoneal dialysis solution, and total Kt/V as well as peritoneal Kt/
V and renal Kt/V were evaluated.
Peritoneal equilibration test
The Peritoneal Dialysis Unit routinely perform PET monitoring to each patient one month
after the begining of the treatment, and then repeat the test approximately every 6 months. In
this study, samples used for EV analyses were obtained at the same time that a routine PET
was perfomed. All patients included in the study were stable as for the PET functional result
(ie, no changes were detected from their initial test). Samples were obtained between June and
September 2014.
Peritoneal equilibration tests were performed with 3.87% glucose solution. The test bag was
drained and reinfused at 60 min as reported[14]. A blood sample was withdrawn at 240 min
and dialysate samples were taken from the pre-infusion bag, and at 0, 60, 120, and 240 min.
Urea, creatinine, glucose, sodium, and potassium were analysed in all samples; urate, phos-
phate, total protein, albumin, were analysed in blood and dialysate samples at 240 min (Cobas
711 Roche diagnostics, Switzerland). A correction was applied for plasma water concentration
for small solutes in the blood sample and, in the dialysate sample, creatinine concentration
was corrected for the presence of glucose.
Calculations
Dialysate to plasma (D/P) ratios for urea and creatinine, and dialysate to baseline dialysate
ratios (D/Do) for glucose were calculated. The mass transfer area coefficients (MTAC) for
urea, creatinine, glucose, urate, phosphate, and potassium were calculated according to
Waniewski et al. [15], using F = 0.5. Peritoneal clearances of total protein and albumin were
also calculated. All parameters were corrected for 1.73 m2 surface area.
Ultrafiltration in PET at 240 min was calculated as the difference between the drained vol-
umes and the initial volume, as follows:
Uf240 min ðmlÞ ¼ ðVtÞ   ðV0Þ
where Uf, ultrafiltration; t, time (min); V, volume (mL).
Statistical analyses of patient data
Data are presented as median (rank). Quantitative data of the two groups were compared
using U-Mann-Whitney test, while qualitative data of the groups were analysed using Fisher’s
test. (SPSS, version 18.0, Chicago, IL, USA). Statistical significance was defined as p<0.05.
Isolation of EVs from PDE
Isolation of EVs from the concentrated PDE was based on a modification of a previous method
described by our group[16]. Five hundred mL PDE were centrifuged at 3,000 g for 5 min
immediately after collection. The supernatant was filtered through a 0.2 μm filter and concen-
trated using a Centricon plus-70 filter unit (100 kDa cut-off; Millipore, Bedford, MA). In brief,
supernatants were loaded onto the Centricon filter and centrifuged at 2,800 g for 30 min. This
step was repeated using one filter unit for each sample until the total volume was processed.
The retained volume (ranging from 0.8 mL to 2 mL) of concentrated PDE was loaded onto a
size-exclusion chromatography (SEC) column.
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Size-exclusion chromatography
Up to 2 mL of concentrated PDE samples were loaded onto 12 mL of Sepharose-CL2B (Sigma-
Aldrich, St. Louis, MO, USA) columns equilibrated in citrate buffer (phosphate-buffered
saline, PBS/0.32% citrate) and eluted with PBS. Immediately after, up to 20 fractions of approx-
imately 0.5 mL each were collected and keep at -80˚C until further use.
Protein concentration
The protein concentration was measured by Bradford assay (10 μL of sample; Bio-Rad labora-
tories, USA) with a standard linear curve based on bovine serum albumin (BSA) (Sigma
Aldrich).
Flow cytometry
Flow cytometry was used to identify fractions containing EVs according to their tetraspanin
content and performed as reported before[16]. Antibodies anti-CD9 (1:10, Clone VJ1/20),
anti-CD63 (1:10, Clone TEA 3/18), or polyclonal isotype (1:5000, Abcam (ab37355), Cam-
bridge, UK) were added to samples an incubated at 4˚C for 30 min. After two washes, beads
were incubated with FITC-conjugated secondary antibody (SouthernBiotech, Birmingham,
AL) and analysed in a FacsVerse flow cytometer (BD Biosciences, San Jose, CA). Approxi-
mately 10,000 beads/sample were acquired and analysed using the Flow Jo software (Tree Star,
Ashland, OR). In all samples, the top three tetraspanin-containing chromatographic fractions
(those containing EVs) were pooled and used in experiments thereafter.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
Protein content profile of EV fractions was determined using sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis (SDS-PAGE). Ten μL of each sample were diluted in the same
volume of Laemmli buffer (2x; Bio-Rad) with β-mercaptoethanol (5%; Bio-Rad) and boiled at
95˚C for 10 min. Then, 20 μL of the mix were loaded into a gel (Mini-Protean TGX gel; 10%
polyacrylamide; Bio-Rad). Electrophoresis was performed for 1 hour at 150V. Gels were the
stained with SilverQuest (Invitrogen) following the manufacturer’s instructions.
Nanoparticle tracking analysis
To determine the concentration and size distribution of EVs, nanoparticle tracking analysis
(NTA) was performed in a Nanosight LM10 (Malvern Instruments Ltd, Malvern, UK) with
charge-coupled device (CCD) camera (model F-033) and a 638 nm laser. Data were analysed
with the NTA V3.0 software. Samples were diluted 10- to 40-fold with 0.2 μm-filtered PBS to
yield 40 to 120 particles/frame as recommended by the manufacturer. Up to 3 videos of 60 sec-
onds each were recorded for each sample with the camera shutter at 30.02 ms, gain set at 650
and camera level at 16. Blur and Max Jump Distance were set automatically, detection thresh-
old was set to 5.
Cryo-electron microscopy
Ten μL of pooled tetraspanin-peak fractions were used for cryoelectron microscopy (cryo-
EM). Each sample was laid on Formvar-Carbon EM grids, frozen and immediately analysed
with Jeol JEM 2011 transmission electron microscope equipped with a 626 Gatan cryoholder
operating at an accelerating voltage of 200 kV. The samples, maintained at -182˚C during
imaging, were recorded on a Gatan Ultrascan cooled CCD camera under low electron dose
Proteomic analysis of peritoneal dialysis efflux extracellular vesicles
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conditions to minimize electron bean radiation. The ImageJ software (NIH) was used to mea-
sure EVs size.
Mass spectrometry analysis
Protein content of PDE-EV-enriched fractions was analysed by liquid chromatography fol-
lowed by mass spectrometry (LC-MS/MS) on a LTQ Orbitrap Velos (Thermo Fisher, Carls-
bad, CA). Samples were reduced with DTT, alkylated with ioidoacetamide and precipitated
with trichloroacetic acid. The samples were then washed with acetone and reconstituted in
urea before an overnight digestion with trypsin.
Proteomic data processing and analysis
Raw data files were analysed with Max Quant software[17] (version 1.5.3.30) against Uniprot
human database (downloaded on December 11, 2015, 70,076 proteins). Parameters set for sin-
gle protein identification include: (i) minimum peptide length of 7; (ii) maximum false discov-
ery rate (FDR) for peptides and proteins of 1%; (iii) minimum peptides per protein of 1 and
minimum unique peptides per protein of 0; (iv) the minimum score for modified peptides was
set to 40; (v) main search error of 4 ppm. In addition, in all searches cysteine carbamidomethy-
lation was established as a fixed modification and methionine oxidation and acetylation of the
N-terminus were established as variable modifications, with a maximum number of modifica-
tions per peptide set to 5. Proteins identified as potential contaminants, those only identified
by site or by a reverse sequence, as well as proteins with less than 2 unique peptides were not
further considered.
Further analyses of proteins were made using the Intensity-Based Absolute Quantification
(iBAQ) values obtained from MaxQuant, and analysed using Perseus software[18] (version
1.5.6.0), InteractiVenn [19] and the EVs specific databases EVpedia [20], Exocarta [21] and
Vesiclepedia [22].
iBAQ values were logarithmized to perform the subsequent analysis such as correlation
plots, hierarchical clustering analysis (HCA), Principal Component Analysis (PCA) and vol-
cano plot. Gene Ontology (GO) terms for biological process and cellular components were
annotated using Perseus. For PCA, data imputation to substitute non-quantified values with
low valid intensities based on normal distribution (down-shift of 1.8 and distribution width of
0.3) was performed. Non-supervised HCA was also done after data imputation. Additional
HCA was performed considering only the 63 "core" proteins shared by all samples, in both
cases after data normalization with z-score and using Euclidean distance in columns and rows.
A volcano plot was used to identify the most significant proteins by plotting fold-change differ-
ence of log2 iBAQ on x axis and -log2 (p-value) on y axis. The two-sided unpaired t-test was
performed with FDR set at 0.05 and s0 at 0.1.
Results
Clinical and epidemiological characteristics of dialysis patients
The study included 9 patients divided in two groups depending on the time on PD: patients
with less than 10 months on PD (Newly-Enrolled Patients or NEPs), and patients on PD for
more than 18 months (Longer-Treated Patients or LTPs). Clinical data are summarized in
Table 1 and detailed per patient in S1 Table. Only 1 patient of the LTP group had type 2 diabe-
tes mellitus, while 3 NEPs and 4 LTPs had hypertension. Regarding the modality of PD, CAPD
was used in all NEPs and in 3 patients LTPs. Two LTPs patients used APD. No statistical dif-
ferences were observed in any of these parameters between both groups.
Proteomic analysis of peritoneal dialysis efflux extracellular vesicles
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Based on PET results (summarized in Table 2 and detailed in S2 Table), 2 NEP patients
were classified as "medium transport" and the other 2 NEP patients as "high transport". In the
LTP group, 3 patients were classified as "low transport" and 2 patients as "medium transport".
The median 4-hour ultrafiltration was 402 (676–82) mL, and the median of total Kt/V was
2.14 (2.37–1.78). Again, no statistically significant differences were found.
Isolation of PDE-EVs from PD patients
Peritoneal efflux-derived EVs were isolated from patients following a modification of the SEC
method (Fig 1). As shown, PDE samples (500 mL) were cleaned from debris, ultra-filtered
using a 100 kDa ultrafiltration unit, and loaded into SEC columns. Collected fractions contain-
ing higher amount of proteins eluted well-after fraction 10 (Fig 2A). When the same chro-
matographic fractions were analysed for their tetraspanin markers, CD9 and CD63 expression
were found mostly in fractions 6 to 10 (Fig 2A) among the different samples, indicating the
presence of PDE-EVs in those fractions.
Then, NTA analyses of these fractions showed that PDE-EVs had a modal distribution
mainly ranging from 100 to 200 nm (Fig 2B). Regarding particles’ concentration, a faint non-
significant reduction in the number of detected particles was found in LTPs compared to
NEPs (Fig 2C).
Further confirmation of the presence of PDE-EVs in tetraspanin fractions was obtained
using Cryo-EM. Images revealed membrane-limited round shaped vesicles (Fig 2D). All
Table 1. Basal characteristics of the patients.
n = 9 patients NEPs
<10 months
(n = 4 patients)
LTPs
>18 months
(n = 5 patients)
P-valueb
Age (years) 53.5 (42.0–62.0)a 54.0 (27.0–75.0)a 0.806
Time on PD (months) 7.0 (5.0–10.0)a 24.0 (21.0–67.0)a 0.0001
DM (n) 0 1 1.000
HTA (n) 3 4 1.000
CAPD/APD (n) 4/0 3/2 0.444
Icodextrin (n) 3 4 1.000
aMedian (rank)
b p-values for quantitative data were calculated using U-Mann-Whitney test while qualitative data of the groups were analysed using Fisher’s test.
DM, diabetes mellitus; HTA, hypertension; CAPD, Continuous Ambulatory Peritoneal Dialysis; APD, Automated Peritoneal Dialysis.
https://doi.org/10.1371/journal.pone.0176987.t001
Table 2. PET characteristics of the patients.
n = 9 patients NEPs
<10 months
(n = 4 patients)
LTPs
>18 months
(n = 5 patients)
P-value b
D/P creatinine 0.75 (0.64–0.89) a 0.56 (0.47–0.75) a 0.190
D/P urea 0.84 (0.75–0.87) a 0.79 (0.76–0.89) a 1.000
D/D0 glucose 0.22 (0.20–0.26) a 0.35 (0.24–0.39) a 0.063
UF 240 min (mL) 310.0 (82.0–482.0) a 577.0 (116.0–676.0) a 0.286
a Median (rank)
b p-values were calculated using U-Mann-Whitney test
https://doi.org/10.1371/journal.pone.0176987.t002
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Fig 1. Schematic representation of peritoneal dialysis efflux sample processing and EV isolation.
https://doi.org/10.1371/journal.pone.0176987.g001
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together these data indicated that PDE-EVs could be obtained from NEPs and LTPs undergo-
ing PD.
Proteomic analysis of PDE-EV fractions
As EVs fractions contain low protein amounts, a preliminary protein content analysis was per-
formed using SDS-PAGE experiments to further characterize the PDE-EVs profile. Different
fractions from one patient were analysed and silver-stained gels revealed the presence of some
bands in fraction 7 (F7, EV-peak fraction), whilst in fractions 11 and 18 (F11, F18, protein frac-
tions) the number and intensity of the bands increased, clearly revealing the presence of bulk
proteins (Fig 3A). When pooled EV fractions from each sample (as detected in Fig 2A) were
analysed, silver stained gels showed clearer bands although still less abundant compared to
protein-containing fractions (Fig 3B, P2 and P3).
Peritoneal efflux-derived EVs obtained from each NEP (n = 4) and each LTP (n = 5) were
further studied to determine their specific peptide profiles using LC-MS/MS. Only proteins
identified by at least 2 unique peptides were considered. Overall, a total of 274 proteins were
Fig 2. Characterization of PDE-EVs. PDE concentrated samples were further separated using SEC. Up to
20 fractions were recovered and analysed in each sample. In plot A, fractions were analysed for their protein
content by BCA (black line). Protein concentration from the different EV-enriched fractions was measured by
absorbance at 280nm and calculated using a BSA standard curve. Also, the expression of the EV markers
CD9 (black squares) and CD63 (white circles) was determined by flow cytometry. The dotted line represents
the isotype control. The left axis represents the total protein content (mg/ml) and the right axis shows the
median fluorescence intensity (MFI). For each sample, the three fractions with the highest CD9 and CD63
MFI were pooled for further analyses. A representative plot from 9 experiments is shown. Plot B shows a
representative NTA of PDE-EVs (n = 9). Plot C depicts particle concentration determinations, also performed
by NTA analyses, in n = 4 NEPs and n = 5 LTPs. Finally, pooled PDE-EVs were visualized by cryo-EM (Fig
2D).
https://doi.org/10.1371/journal.pone.0176987.g002
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identified. Among NEPs samples, a mean of 211 proteins were identified (211±8), from which
73% (154 proteins) were found in all patients (Fig 4A), revealing a high intragroup similarity.
This was further confirmed by multi-scatter plot showing a Pearson Correlation mean “r”
value of 0.76±0.08 (mean±sd) (Fig 4B). Regarding LTPs, a mean of 147 proteins (147±23) were
identified, from which only 43% (63 proteins) were shared among all LTPs (Fig 4C), with a
Fig 3. Protein profiling SEC fractions by SDS-PAGE. (A) Silver staining SDS-PAGE of several SEC fractions, including a pre-tetraspanin fraction (F5),
a high tetraspanin-containing fraction (F7) and non-EV protein proximal (F11) and distal (F18) fractions. In plot B, pooled tetraspanin-rich fractions from
two different experiments (P2 and P3) are shown. Molecular weight markers are also depicted.
https://doi.org/10.1371/journal.pone.0176987.g003
Proteomic analysis of peritoneal dialysis efflux extracellular vesicles
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Fig 4. Protein analyses from PDE-EVs. Venn diagrams showing overlapping proteins from n = 4 NEPs (A) and n = 5
LTPs (C) are shown. Correlation multi-scatter plots to analyse the correlation within NEPs (B) and LTPs (D) samples.
Pearson Correlation “r” values are labelled on each plot. (E) Venn diagram of the proteins shared by all NEPs
compared to the proteins shared by all LTPs.
https://doi.org/10.1371/journal.pone.0176987.g004
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PLOS ONE | https://doi.org/10.1371/journal.pone.0176987 May 10, 2017 10 / 20
Pearson Correlation mean “r” value of 0.56±0.20 (Fig 4D). Interestingly, all 63 proteins shared
by LTPs were identified also in all NEPs (Fig 4E). These "core" proteins (listed in Table 3)
included proteins unequivocally related to EVs, such as CD81, Galectin 3-binding protein
(LGALS3BP), Ezrin (EZR) and several members of the Apolipoprotein (APO) and Annexin
(ANXA) families, among others.
To further evidence the differences between both groups, a PCA was performed. Based on
component 1, which accounts for the 52.6% of the variability between the samples, both groups
were segregated based on their time on PD (Fig 6A). The Gene Ontology biological processes
analysis of component 1 revealed that most enriched terms in NEP in comparison to LTP are
those related to the immune system (Fig 6B). Additionally, HCA of the 274 proteins detected
among all samples also clustered most patients based on their time on PD (Fig 6C). Finally, a
volcano plot comparing the protein expression between the two groups evidenced the statisti-
cally significant proteins showing a significantly different level of expression (Fig 6D). These
analyses revealed that up to 67 proteins were significantly overexpressed in NEP than LTP
(p-value <0.05).
In addition, a HCA performed exclusively on the 63 "core" proteins identified in all samples
resulted in the segregation of 8 out of 9 patients based on time in PD, in a very similar way to
the HCA performed with all the proteins (Fig 5).
Discussion
In this study we report, for the first time to our best knowledge, the presence, isolation and
characterization of PDE-EVs from patients on PD.
Peritoneal dialysis is a convenient treatment for end-stage kidney disease patients waiting
for a kidney transplant. Studies have reported better survival rates, quality of life and indepen-
dence of PD patients compared to haemodialysis patients[23,24]. However, during the treat-
ment, fibrotic changes reduce the ultrafiltration capacity of the PM, meaning that many
patients have to discontinue treatment.
Current monitoring of the PM function (the PET), requires patients’ attendance to the dial-
ysis centre, is time-consuming and only shows alterations when the PM is in an advanced state
of fibrosis. Time-delays on identifying PMs’ dysfunction may carry dangerous complications,
and even lead to the death of the patient. Therefore, finding early biomarkers of PM dysfunc-
tion that minimally disturb patients’ daily life may help to overcome these limitations, contrib-
ute keeping functional PMs for longer periods and improve patients’ management. Several
studies have searched for biomarkers in PDE correlating with PM function, detection of fibro-
sis, and/or the failure of the technique (reviewed in[25]). Proteomic studies of mesothelial cell
lines[7] and transcriptome analysis in rats[26] have reported differences between the protein
and miRNA content, respectively, of cells exposed or non-exposed to peritoneal liquids.
It is of current acceptance that information contained in EVs may serve as biomarkers of
pathological situations. Biomarkers for kidney pathology have been described in urine EVs
[12,27], and serum/plasma EVs have been also related to multiple pathologies[28]. It may be
therefore envisaged that PDE-EVs may also provide useful information about the state and
function of the PM. Such information could help the clinician to accommodate the treatment
to enhance the optimal functionalism of the PM.
PDE-EVs were equally identified in all patients from both NEPs and LTPs groups. SEC-iso-
lated vesicles contained in the tetraspanin rich fractions had a size and morphology compatible
with EV, as shown by NTA and cryo-EM analyses. As reported before in urine[29] and plasma
samples[30], our results point to SEC as an efficient technique to isolate EVs also from PDE
samples. Importantly, SEC permits the segregation of EVs from the bulk of proteins found in
Proteomic analysis of peritoneal dialysis efflux extracellular vesicles
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samples, thus allowing more accurate analyses of the EV-protein content and enabling the
search for minimally expressed proteins. In line, SDS-PAGE results confirmed that EVs were
cleanly separated from other major components of the PDE, and preliminary proteomic analy-
sis of SEC-isolated EVs identified a number of well-defined EV-related proteins. Importantly,
all these results are in accordance with the recommendations of the International Society for
Extracellular Vesicles (ISEV) to identify EVs in a given sample [31], thus validating SEC to iso-
late EVs also from PDE.
Having identified EVs in all samples, and to further explore possible differences in this pilot
study, patients were distributed in two arbitrary groups based on their median time on PD.
Both groups did not show major differences in any of the parameters analysed, nor in the PET
test. However, a slightly (not significant) reduced number of EVs and also a reduced number
of proteins were identified in the PDE-EVs from the LTP group compared to NEPs., It was
also interesting to note that a "core" of proteins were identified in both groups, although show-
ing some differences in their level of expression. These "core" proteins included most proteins
unequivocally related to EVs. Whether these differences may anticipate a possible worsening
of the ultrafiltration capacity of the membrane not detected by PET analyses need further
investigation and validation in a wider cohort of patients.
Fig 5. Hierarchical clustering analysis of the 63 “core” proteins. Samples and the 63 proteins shared by
all samples were clustered with HCA associated with a heat map. Names of the codifying genes are shown.
https://doi.org/10.1371/journal.pone.0176987.g005
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Fig 6. Proteins analyses from PDE-EVs. (A) Two dimensional scatter plot of Principal Component Analysis (PCA) showing component 1 and 2, which
account for 52.6% and 20.9%, respectively, the variability of all the 274 proteins. NEPs (circles) and LTPs (squares) are separated by component 1. A
dashed line circle indicates grouped NEPs. (B) Table with Gene Ontology biological process enriched terms for component 1 with their corresponding
Benjamini-Hochberg FDR values is shown (all the listed terms have a Benj. Hoch. FDR <0.05). (C) HCA associated with a heat map of the 274 proteins
(rows) and the samples (columns). (D) A volcano plot was performed to determine significantly differentially expressed proteins between groups. Each
circle represents a protein, being statistically significant proteins with this parameters shown as filled circles. Proteins with p-value <0.01 are represented
as bigger filled circles.
https://doi.org/10.1371/journal.pone.0176987.g006
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Since this study has consistently demonstrated that EVs can be isolated from concentrated
PDE, it seems reasonable to think that these EVs could be used as a source of biomarkers. In
addition, the non-invasive origin of the sample and the reduced inconvenience for patients
point to the analysis of PDE-EVs as a next step in the definition of early biomarkers of ultrafil-
tration failure in peritoneal dialysis.
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